REPLIMUNE GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.42 USD | +4.39% |
|
-0.47% | -23.84% |
| 08/04 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
| 26/03 | Replimune Group, Inc. Announces Management Changes | CI |
Chart calendar Replimune Group, Inc.
f474757e36cab1c.jusj9Isz2B8y_aQuZOExZ5a5Uc-v4FJtoP0KxzX2xNM.xrhBprth4GUHiMxbVbN9I_jdGradqhMb86xQ9wWCnYDHg2i63FCXLFGE9Q~2f923d423b5a6600a92212ca3dd2b69c
Upcoming events on Replimune Group, Inc.
Past events on Replimune Group, Inc.
| 08/04/2024 06:30 pm | American Association for Cancer Research Meeting - Abstract No - 2467 |
| 07/04/2024 10:30 pm | American Association for Cancer Research Meeting - Abstract No - 9269 |
| 14/03/2024 08:15 pm | Barclays Global Healthcare Conference - Fireside Chat |
| 13/03/2024 | Jefferies Biotech on the Bay Summit |
| 12/03/2024 11:50 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 08/02/2024 06:30 pm | Q3 2024 Earnings Release |
| 09/01/2024 12:45 am | JPMorgan Healthcare Conference |
| 05/12/2023 06:30 pm | Business Update Call |
| 07/11/2023 06:30 pm | Q2 2024 Earnings Release |
| 07/09/2023 12:30 am | Annual General Meeting |
| 09/08/2023 | Wedbush PacGrow Healthcare Conference |
| 08/08/2023 11:00 pm | BTIG Biotechnology Conference |
| 03/08/2023 05:30 pm | Q1 2024 Earnings Release |
| 08/06/2023 10:30 pm | Jefferies Global Healthcare Conference |
| 05/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS6106 |
| 05/06/2023 06:30 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS4178 |
| 05/06/2023 06:30 pm | American Society of Clinical Oncology Conference - Abstract Number: TPS3628 |
| 03/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: 9509 |
| 03/06/2023 11:45 pm | American Society of Clinical Oncology Conference - Abstract Number: 9527 |
| 18/05/2023 05:30 pm | Q4 2023 Earnings Release |
Annual results
| Fiscal Period | March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -30,8 -35,1 12.15% | 0,00 0,00 - | 0,00 0,00 - | -116 -118 1.95% | -175 -176 0.78% | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -30,9 -41,0 24.53% | -56,2 -57,1 1.55% | -80,0 -78,4 -2.01% | -118 -118 -0.69% | -177 -169 -4.69% | -227 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -30,8 -41,5 25.71% | -52,6 -53,2 1.12% | -80,9 -79,6 -1.54% | -118 -117 -0.82% | -174 -169 -2.66% | -212 |
|
Net income Million USD | Released Forecast Spread | -30,8 -41,4 25.54% | -52,6 -53,2 1.06% | -80,9 -79,6 -1.6% | -118 -117 -0.83% | -174 -169 -2.85% | -213 |
|
EPS USD | Released Forecast Spread | -1,33 -1,51 11.9% | -1,54 -1,57 2% | -1,75 -1,76 0.43% | -2,26 -2,28 0.72% | -2,99 -2,91 -2.78% | -3,17 |
| Announcement Date | 28/06/19 | 03/06/20 | 20/05/21 | 19/05/22 | 18/05/23 | - |
Quarterly results
| Fiscal Period | March | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -29,7 -29,8 0.45% | -32,0 -31,2 -2.44% | -40,9 -33,4 -22.55% | -41,6 -42,6 2.35% | -41,6 -43,2 3.61% | -53,0 -44,0 -20.57% | -55,6 -54,1 -2.8% | -63,8 -57,1 -11.84% | -56,5 -64,3 12.11% | -56,1 | -57,9 | -58,8 | -60,1 | -61,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -29,7 -29,4 -0.88% | -31,7 -30,7 -3.39% | -42,3 -32,9 -28.58% | -43,1 -42,1 -2.47% | -39,7 -42,7 7.11% | -49,0 -42,2 -15.9% | -49,4 -51,8 4.69% | -60,2 -55,8 -7.98% | -50,6 -60,6 16.43% | -52,9 | -54,8 | -56,1 | -56,8 | -58,5 |
|
Net income Million USD | Released Forecast Spread | -29,7 -29,4 -0.88% | -31,7 -30,7 -3.37% | -42,3 -32,9 -28.5% | -43,1 -42,0 -2.54% | -39,7 -42,8 7.32% | -49,2 -43,1 -14.28% | -49,6 -51,8 4.3% | -60,0 -54,6 -9.97% | -51,1 -61,7 17.11% | -53,6 | -54,4 | -54,4 | -54,1 | -54,4 |
|
EPS USD | Released Forecast Spread | -0,57 -0,58 1.33% | -0,60 -0,60 -0.66% | -0,78 -0,63 -24.06% | -0,79 -0,78 -0.99% | -0,69 -0,77 10.39% | -0,74 -0,69 -7.59% | -0,75 -0,84 10.84% | -0,90 -0,86 -4.48% | -0,77 -0,94 17.77% | -0,80 | -0,80 | -0,78 | -0,79 | -0,80 |
| Announcement Date | 03/02/22 | 19/05/22 | 04/08/22 | 03/11/22 | 09/02/23 | 18/05/23 | 03/08/23 | 07/11/23 | 08/02/24 | - | - | - | - | - |
More events
Past sector events for Replimune Group, Inc.
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 27/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- REPL Stock
- Calendar Replimune Group, Inc.
